Nintedanib Esylate
Brand name: Ofev
Rank #24 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$703.7M
Total Cost
53,928
Total Claims
$703.7M
Total Cost
1,757
Prescribers
$13K
Cost per Claim
2,118
Beneficiaries
54,796
30-Day Fills
$401K
Avg Cost/Provider
31
Avg Claims/Provider
Share of Medicare Part D Spending
0.26%
of total Medicare Part D spending
$703.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $703.7M total
🔎 Data Overview
Ranked #24 out of 500 drugs tracked by total cost. Nintedanib Esylate represents a significant portion of Medicare drug spending.
At $13,049 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $400,527 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $332,260 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Nintedanib Esylate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Pedro Sepulveda | Pulmonary Disease | San Antonio, TX | 308 | $4.2M |
| 2 | Bradley Sanville | Pulmonary Disease | Sacramento, CA | 263 | $3.4M |
| 3 | Robert Kaner | Pulmonary Disease | New York, NY | 254 | $3.2M |
| 4 | Julie Gebhardt | Nurse Practitioner | Schaumburg, IL | 226 | $3.0M |
| 5 | Traci Adams | Pulmonary Disease | Dallas, TX | 213 | $2.9M |
| 6 | Amber Yopp | Pharmacist | Durham, NC | 225 | $2.9M |
| 7 | Bradford Bemiss | Pulmonary Disease | Maywood, IL | 201 | $2.7M |
| 8 | John Huggins | Pulmonary Disease | Charleston, SC | 224 | $2.7M |
| 9 | Deljean Buenaventura | Nurse Practitioner | Phoenix, AZ | 201 | $2.5M |
| 10 | Lillie Morgan | Pulmonary Disease | Grand Rapids, MI | 202 | $2.5M |
| 11 | Murali Ramaswamy | Pulmonary Disease | Greensboro, NC | 179 | $2.5M |
| 12 | Rachana Krishna | Pulmonary Disease | Charleston, SC | 187 | $2.4M |
| 13 | Leah Fingerman | Nurse Practitioner | Atlanta, GA | 188 | $2.4M |
| 14 | Annette Su | Nurse Practitioner | Stanford, CA | 175 | $2.3M |
| 15 | Girish Nair | Pulmonary Disease | Royal Oak, MI | 182 | $2.3M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology